Stacey Chuma

1.3k total citations
38 papers, 843 citations indexed

About

Stacey Chuma is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Stacey Chuma has authored 38 papers receiving a total of 843 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Genetics, 21 papers in Hematology and 18 papers in Pathology and Forensic Medicine. Recurrent topics in Stacey Chuma's work include Chronic Lymphocytic Leukemia Research (24 papers), Lymphoma Diagnosis and Treatment (16 papers) and Multiple Myeloma Research and Treatments (14 papers). Stacey Chuma is often cited by papers focused on Chronic Lymphocytic Leukemia Research (24 papers), Lymphoma Diagnosis and Treatment (16 papers) and Multiple Myeloma Research and Treatments (14 papers). Stacey Chuma collaborates with scholars based in United States, Sweden and Germany. Stacey Chuma's co-authors include Irene M. Ghobrial, Paul G. Richardson, Kenneth C. Anderson, Steven P. Treon, Diane Warren, Renee Leduc, Brianna Harris, Meghan Rourke, Edie Weller and Janet Kunsman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Stacey Chuma

38 papers receiving 834 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stacey Chuma United States	10	598	516	289	260	253	38	843
Michael Voralia Canada	11	263 0.4×	309 0.6×	263 0.9×	149 0.6×	229 0.9×	25	681
Jiaji G. Chen United States	9	481 0.8×	410 0.8×	160 0.6×	207 0.8×	83 0.3×	18	558
Елена Бибикова United States	9	326 0.5×	236 0.5×	153 0.5×	141 0.5×	185 0.7×	16	525
L. Escribano Spain	7	205 0.3×	139 0.3×	184 0.6×	292 1.1×	128 0.5×	11	537
Michaela Patz Germany	8	217 0.4×	145 0.3×	74 0.3×	100 0.4×	209 0.8×	12	441
Joy Knight United States	8	181 0.3×	290 0.6×	123 0.4×	154 0.6×	247 1.0×	13	633
Arnau Montraveta Spain	12	236 0.4×	182 0.4×	119 0.4×	96 0.4×	281 1.1×	17	492
Viralkumar Patel United States	7	182 0.3×	117 0.2×	61 0.2×	78 0.3×	120 0.5×	11	349
Shih‐Shih Chen United States	12	321 0.5×	214 0.4×	76 0.3×	236 0.9×	126 0.5×	41	494
Ellen Neylon United States	12	126 0.2×	371 0.7×	79 0.3×	167 0.6×	156 0.6×	27	571

Countries citing papers authored by Stacey Chuma

Since Specialization

Citations

This map shows the geographic impact of Stacey Chuma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stacey Chuma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stacey Chuma more than expected).

Fields of papers citing papers by Stacey Chuma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stacey Chuma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stacey Chuma. The network helps show where Stacey Chuma may publish in the future.

Co-authorship network of co-authors of Stacey Chuma

This figure shows the co-authorship network connecting the top 25 collaborators of Stacey Chuma. A scholar is included among the top collaborators of Stacey Chuma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stacey Chuma. Stacey Chuma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ghobrial, Irene M., Chia‐Jen Liu, Robert Redd, et al.. (2019). A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. Clinical Cancer Research. 26(2). 344–353. 79 indexed citations

Ghobrial, Irene M., Chia‐Jen Liu, Raymond P. Perez, et al.. (2018). A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. Blood. 132(Supplement 1). 3263–3263. 3 indexed citations

Ghobrial, Irene M., Robert Redd, Philippe Armand, et al.. (2015). Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. Leukemia. 29(12). 2338–2346. 26 indexed citations

Laubach, Jacob P., Noopur Raje, Philippe Armand, et al.. (2014). Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM).. Journal of Clinical Oncology. 32(15_suppl). 8534–8534. 1 indexed citations

Ghobrial, Irene M., Jacob P. Laubach, Kenneth H. Shain, et al.. (2014). Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma. Blood. 124(21). 5777–5777. 3 indexed citations

Ghobrial, Irene M., Kenneth H. Shain, Ranjit Banwait, et al.. (2013). Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma. Blood. 122(21). 1947–1947. 3 indexed citations

Ghobrial, Irene M., Thomas E. Witzig, Morie A. Gertz, et al.. (2013). Long‐term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. American Journal of Hematology. 89(3). 237–242. 49 indexed citations

Ghobrial, Irene M., Jacob P. Laubach, Noopur Raje, et al.. (2013). Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, and Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma. Blood. 122(21). 1948–1948. 1 indexed citations

Ghobrial, Irene M., Federico Campigotto, Timothy J. Murphy, et al.. (2013). Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia. Blood. 121(8). 1296–1303. 37 indexed citations

10.

Ghobrial, Irene M., Morie A. Gertz, Betsy LaPlant, et al.. (2010). Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia. Journal of Clinical Oncology. 28(8). 1408–1414. 102 indexed citations

11.

Ghobrial, Irene M., Wanling Xie, Swaminathan P. Iyer, et al.. (2010). Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. American Journal of Hematology. 85(9). 670–674. 101 indexed citations

12.

Ghobrial, Irene M., Edie Weller, Ravi Vij, et al.. (2010). Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib. Blood. 116(21). 990–990. 5 indexed citations

13.

Ghobrial, Irene M., Fangxin Hong, Swaminathan P. Iyer, et al.. (2010). Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia. Journal of Clinical Oncology. 28(8). 1422–1428. 116 indexed citations

14.

Ghobrial, Irene M., Aldo M. Roccaro, Fangxin Hong, et al.. (2010). Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's Macroglobulinemia. Clinical Cancer Research. 16(3). 1033–1041. 96 indexed citations

15.

Leduc, Renee, Marybeth Nelson, Amy Sam, et al.. (2009). A573 Phase I Trial of CCI-779 and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma. Clinical Lymphoma & Myeloma. 9. S86–S86. 1 indexed citations

16.

Ghobrial, Irene M., Swaminathan P. Iyer, Stacey Chuma, et al.. (2009). Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom macroglobulinemia. Journal of Clinical Oncology. 27(15_suppl). 8535–8535. 2 indexed citations

17.

Ghobrial, Irene M., Fangxin Hong, Swaminathan P. Iyer, et al.. (2009). Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.. Blood. 114(22). 2727–2727. 5 indexed citations

18.

Ghobrial, Irene M., Swaminathan P. Iyer, Ashraf Badros, et al.. (2009). Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia.. Blood. 114(22). 3752–3752. 5 indexed citations

19.

Ghobrial, Irene M., Ravi Vij, Nikhil C. Munshi, et al.. (2009). Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma.. Blood. 114(22). 748–748. 9 indexed citations

20.

Ghobrial, Irene M., Xavier Leleu, Nancy Rubin, et al.. (2008). Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom Macroglobulinemia (WM).. Blood. 112(11). 1010–1010. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact